You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Mycotoxin Neutralization Treatment

    SBC: Physical Optics Corporation            Topic: CBD152003

    To address the Chemical and Biological Defense programs (CBDs) need for medical countermeasures against mycotoxin intoxication, PhysicalOptics Corporation (POC) proposes to develop a new Mycotoxin Neutralization Treatment (MyNT). This proposed solution is based on neutralizingmycotoxin from its deleterious effects by acting on multiple levels of mycotoxin metabolism through the novel combination o ...

    SBIR Phase I 2016 Department of DefenseOffice for Chemical and Biological Defense
  2. Human monoclonal antibodies as countermeasures for T-2 mycotoxin

    SBC: ABZYME THERAPEUTICS LLC            Topic: CBD152003

    Mycotoxins are fungal toxins to which exposure frequently results in incapacitation or even in death. Natural outbreaks of mycotoxin poisoningare common worldwide. Due to its physical-chemical properties, high toxicity and relative ease to produce, mycotoxin T-2 is classified as apotential biological warfare agent. Currently there are no FDA approved medical countermeasures available for T-2 mycot ...

    SBIR Phase I 2016 Department of DefenseOffice for Chemical and Biological Defense
  3. Mycotoxin Adsorption with Hemocompatible Porous Polymer Beads

    SBC: CYTOSORBENTS MEDICAL INC            Topic: CBD152003

    Acute exposure to mycotoxins can lead to systemic toxicity and even death. With no specific treatment available, aflatoxin and trichothecene T-2toxin, in particular, are of concern as potential biological weapons due to their toxicity, thermal and UV stability and easy accessibility. As amedical countermeasure, we propose the development of highly porous polymer beads optimized for removal of afla ...

    SBIR Phase I 2016 Department of DefenseOffice for Chemical and Biological Defense
  4. Exploiting Natural Products-Based Therapeutics for Aflatoxin Mitigation

    SBC: CFD RESEARCH CORPORATION            Topic: CBD152003

    Aflatoxins are a paradigm among fungal produced mycotoxins that are present in food supplies and are strongly associated with increased risk forthe development of hepatocellular carcinoma. Currently, there are no known countermeasures that can selectively mitigate aflatoxin toxicity andthe available options are only symptomatic treatments. To meet this challenge, we propose to harness the microbio ...

    SBIR Phase I 2016 Department of DefenseOffice for Chemical and Biological Defense
  5. Medical Imagery Tailored HEVC (MITH)

    SBC: A-TECH CORPORATION            Topic: DHP14001

    DHP is seeking new image compression technologies that will retain diagnostic quality and reduce the burden of digital medical image transmission on the militarys tactical networks.ATA is proposing to tailor the latest state-of-the-art commercial image compression algorithm, the Main Still Picture Profile of the High Efficiency Video Coding (HEVC) standard, for medical imagery.HEVC has been shown ...

    SBIR Phase II 2016 Department of DefenseDefense Health Agency
  6. Plasmid-seeded aligned nanofibrillar scaffold for acute muscle injury treatment

    SBC: Fibralign Corporation            Topic: DHP14009

    Based on encouraging Phase I feasibility results, we propose developing a novel gene therapy approach to promote guided vascular regeneration in treating extremities after traumatic injury. Our approach is to provide thread-like implants comprised of aligned nanofibrillar collagen scaffolds loaded with Hepatocyte Growth Factor (HGF) vectors (e.g., HGF DNA plasmid, modified mRNA) designed to enhanc ...

    SBIR Phase II 2016 Department of DefenseDefense Health Agency
  7. Use of Highly Porous Polymer Beads to Remove Anti-A and Anti-B Antibodies from Plasma for Transfusion

    SBC: CYTOSORBENTS MEDICAL INC            Topic: DHP15B001

    The ready availability of universal donor plasma to rapidly treat massively bleeding hospital trauma patients and warfighters with combat casualties is a key element of current recommendations for trauma resuscitation, yet universal AB donor plasma is rel

    SBIR Phase I 2016 Department of DefenseDefense Health Agency
  8. Smart Femtosecond Fiber Laser Wound Healing System

    SBC: POLARONYX INC            Topic: DHP15B002

    Based on our success in developing the world first commercial high energy femtosecond fiber laser system and our leading proprietary technology development in ultrashort pulsed fiber laser material processing, PolarOnyx proposes, for the first time, a compact high energy fiber laser based smart wound healing tool to meet with the requirement of this DHP solicitation. It includes a high energy fs f ...

    SBIR Phase I 2016 Department of DefenseDefense Health Agency
  9. Fully Integrated Light Therapy-Based Wound Dressings for Wound Healing Applications

    SBC: LYNNTECH INC.            Topic: DHP15B002

    Between Operation Iraqi Freedom, Operation Enduring Freedom, and Operation New Dawn, the total number of U.S. Casualties (those Wounded in Action) has exceeded 52,000 as of January 30, 2015. These numbers point to the fact that active warfighters in the battlefield are almost constantly exposed to the threat of external penetrating wounds. The goal of combat wound care is to protect open wounds u ...

    SBIR Phase I 2016 Department of DefenseDefense Health Agency
  10. Innovative Wound Regeneration Support Approaches to Enable Rapid Treatment of Wounded Warfighters

    SBC: Zetroz Systems LLC            Topic: A14AT016

    Ultrasound is a therapeutic modality which has been used clinically for 60 years, but has been limited in practice by the complexity of the technology. Recent research has allowed for the development of a portable, wearable, long duration, low intensity therapeutic ultrasound system. The system is powered by battery, and can be applied by a user to deliver up

    SBIR Phase II 2016 Department of DefenseDefense Health Agency
US Flag An Official Website of the United States Government